Regadenoson is a safe and well-tolerated pharmacological stress agent for myocardial perfusion imaging in post-heart transplant patients
- 320 Downloads
The safety and tolerability of regadenoson (REG), a newer adenosine A2a receptor agonist, has not been tested in orthotopic heart transplant (OHT) patients.
Retrospective review of a tertiary care center experience of OHT patients who underwent a REG single-photon emission computed tomography (SPECT) study as part of the work-up for cardiac allograft vasculopathy. The control group included those same patients who had prior adenosine-based SPECT.
A total of 40 patients met the above criteria. Mean time from OHT to adenosine-SPECT and REG-SPECT was 8.2 ± 4.8 years vs 9.8 ± 4.5 years, respectively (P < .001). Both vasodilators had similar side effect profiles (P = .10), produced significant heart rate acceleration and asymptomatic hypotension (P < .001). There were no episodes of bradycardia and/or AV block with REG. Despite adjustment for medication status, adenosine was still associated with more conduction abnormalities (8 vs 1 event with REG, P = .02) including five episodes of 2nd degree AV block (Mobitz type II) and three episodes of sinus pause.
This is the first reported use of REG in OHT patients. REG appears to be safe and well tolerated without significant cardiovascular adverse events.
KeywordsRegadenoson heart transplant safety feasibility SPECT
The senior investigator—Dr Karthik Ananthasubramaniam is on the speaker’s bureau of Astellas Global Pharma Development Inc from whom he also receives significant research grant support for investigator initiated research with Regadenoson, and as the Primary Investigator in prior and ongoing multicenter trials with Regadenoson. The authors would like to acknowledge Drs Wael Jaber and Wael Aljaroudi for their critical review and valuable suggestions.
- 1.Ciliberto GR, Ruffini L, Mangiavacchi M, Parolini M, Sara R, Massa D, et al. Resting echocardiography and quantitative dipyridamole technetium-99m sestamibi tomography in the identification of cardiac allograft vasculopathy and the prediction of long-term prognosis after heart transplantation. Eur Heart J 2001;22:964-71.PubMedCrossRefGoogle Scholar
- 3.Al-Mallah MH, Arida M, Garcia-Sayan E, Assal C, Zegarra GT, Czerska B, et al. Safety of adenosine pharmacologic stress myocardial perfusion imaging in orthotopic cardiac transplant recipients: A single center experience of 102 transplant patients. Int J Cardiovasc Imaging 2010 [Epub ahead of print].Google Scholar
- 4.Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008;1:307-16.PubMedCrossRefGoogle Scholar
- 8.Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009;16:63-72.PubMedCrossRefGoogle Scholar
- 14.Lexiscan (regadenoson) injection [package insert]. Deerfield: Astellas Pharma US, Inc; 2008.Google Scholar
- 15.Adenoscan (adenosine) injection [package insert]. Deerfield: Astellas Pharma US, Inc; 2005.Google Scholar